Immunomedics (Immunomedics) GF Value : $0.00 (As of May. 06, 2024)

View and export this data going back to 1990. Start your Free Trial

What is Immunomedics GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-06), Immunomedics's share price is $87.86. Immunomedics's GF Value is $0.00. Therefore, Immunomedics's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Immunomedics is Not Valued.

Immunomedics (NAS:IMMU) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Immunomedics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	87.86	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunomedics GF Value Related Terms

Thank you for viewing the detailed overview of Immunomedics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunomedics (Immunomedics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunomedics Inc (NAS:IMMU) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 The American Road, Morris Plains, NJ, USA, 07950

Website

http://www.immunomedics.com

Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in clinical and preclinical development. The company is marketing specific diagnostic imaging agents to detect bone infections in Europe, Canada, and Australia. The company has subsidiaries in the Netherlands and Germany to manage sales and clinical trials in Europe.

Executives

Scott A Canute	director	FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Peter Barton Hutt	director
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Khalid Islam	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Venbio Select Advisor Llc	director, 10 percent owner, other: See Remarks	110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh	director, 10 percent owner, other: See Remarks	C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Robert Azelby	director	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Harout Semerjian	director, officer: President and CEO	300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950
Kurt J. Andrews	officer: Chief Human Resources Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Jared Freedberg	officer: General Counsel	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Usama Malik	officer: Chief Business Officer & CFO	300 THE AMERICAN WAY MORRIS PLAINS NJ 07950
Brendan Delaney	officer: Chief Commerical Officer	300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Lorettta M Itri	officer: Chief Medical Officer